New smart drug takes aim at Hard-to-Treat blood cancers
NCT ID NCT07220616
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a new drug called DS3790a for people with certain blood cancers, including B-cell non-Hodgkin lymphoma. The drug is designed to find and attack cancer cells while sparing healthy ones. The study will check safety and how well it works in about 420 adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DS3790a (an antibody-drug conjugate targeting CD37, combined with a chemotherapy-like payload)
What this could lead to
If successful, this could provide a new treatment option for people with certain blood cancers that are hard to treat.
What could go wrong
This is an early (phase 1/2) trial, so the drug may not work or could cause serious side effects. It is not a cure and long-term benefits are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGNew York, New York, 10065, United States
Contact
-
Research Site
RECRUITINGLille, 59037, France
Contact
-
Research Site
RECRUITINGNagoya, 464-8681, Japan
Contact
-
Research Site
RECRUITINGTokyo, 104-0045, Japan
Contact
-
Research Site
RECRUITINGTokyo, 135-8550, Japan
Contact